CD44: From diagnosis to therapy in the journey of oral cancer
Highlights: • Advancements in OSCC treatment have not reduced mortality due to challenges in early diagnosis, highlighting the need for prognostic biomarkers. • CSCs in OSCC fuel chemo-radio-resistance, making their targeting crucial. • CD44, a CSC biomarker, drives cancer progression and resistanc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Oral Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024003297 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Highlights: • Advancements in OSCC treatment have not reduced mortality due to challenges in early diagnosis, highlighting the need for prognostic biomarkers. • CSCs in OSCC fuel chemo-radio-resistance, making their targeting crucial. • CD44, a CSC biomarker, drives cancer progression and resistance. • Elevated CD44 predicts poor outcomes in various cancers. • Studying CD44's role in OSCC is vital for validating its potential as a prognostic marker and therapeutic target. |
|---|---|
| ISSN: | 2772-9060 |